Analgesic effects of intrathecally administered 26RFa, an intrinsic agonist for GPR103, on formalin test and carrageenan test in rats

Neuroscience

Volumn 157, Issue 1, 2008, Pages 214-222

  Yamamoto, T ^a   Wada, T ^b   Miyazaki, R ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b NIPPON SPORT SCIENCE UNIVERSITY   (Japan)

Author keywords

Fos like immunoreactivity; nociceptive transmission; QRFP; RFamide peptide; spinal cord

Indexed keywords

26RFA; CARRAGEENAN; FORMALDEHYDE; G PROTEIN COUPLED RECEPTOR; PROTEIN GPR103; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

AGITATION; ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPINAL CORD DORSAL HORN; SPINAL GANGLION;

ANALGESICS, NON-NARCOTIC; ANIMALS; CARRAGEENAN; DOSE-RESPONSE RELATIONSHIP, DRUG; FORMALDEHYDE; GENES, FOS; HOT TEMPERATURE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INJECTIONS, SPINAL; MALE; NEUROPEPTIDES; PAIN MEASUREMENT; PAIN THRESHOLD; PHYSICAL STIMULATION; RATS; RATS, SPRAGUE-DAWLEY; REACTION TIME; RECEPTORS, G-PROTEIN-COUPLED; SPINAL NERVES;

EID: 54549097932     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2008.08.061     Document Type: Article

References (25)

1. Altier N., Dray A., Menard D., and Henry J.L. Neuropeptide FF attenuates allodynia in models of chronic inflammation and neuropathy following intrathecal or intracerebroventricular administration. Eur J Pharmacol 407 (2000) 245-255
2. Bruzzone F., Lectez B., Alexandre D., Jegou S., Mounien L., Tollemer H., Chatenet D., Leprince J., Vallarino M., Vaudry H., and Chartrel N. Distribution of 26RFa binding sites and GPR103 mRNA in the central nervous system of the rat. J Comp Neurol 503 (2007) 573-591
3. Bruzzone F., Lectez B., Tollemer H., Leprince J., Dujardin C., Rachidi W., Chatenet D., Baroncini M., Beauvillain J.-C., Vallarino M., Vaudry H., and Chartrel N. Anatomical distribution and biochemical characterization of the novel RFamide peptide 26RFa in the human hypothalamus and spinal cord. J Neurochem 99 (2006) 616-627
4. Chaplan S.R., Bach F.W., Pogrel J.W., Chung J.M., and Yaksh T.L. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53 (1994) 55-63
5. Chartrel N., Dujardin C., Anouar Y., Leprince J., Decker A., Clerens S., Do-Rego J.-C., Vandesande F., Llorens-Cortes C., Costentin J., Beauvillain J.-C., and Vaudry H. Identification of 26RFa, a hypothalamic neuropeptide of the RFamide peptide family with orexigenic activity. Proc Natl Acad Sci U S A 100 (2003) 15247-15252
6. Dixon W.J. Efficient analysis of experimental observations. Annu Rev Pharmacol Toxicol 20 (1980) 441-462
7. Fang Q., Guo J., He F., Peng Y.-I., Chang M., and Wang R. In vivo inhibition of neuropeptide FF agonism by BIBP3226, an NPY Y1 receptor antagonist. Peptide 27 (2006) 2207-2213
8. Fukusumi S., Yoshida H., Fujii R., Maruyama M., Komatsu H., Habata Y., Shintani Y., Hinuma S., and Fujino M. A new peptidic ligand and its receptor regulating adrenal function in rats. J Biol Chem 278 (2003) 46387-46395
9. Gouarderes C., Jhamandas K., Sutak M., and Zajac J.-M. Role of opioid receptors in the spinal antinociceptive effects of neuropeptide FF analogues. Br J Pharmacol 117 (1996) 493-501
10. Hammond D.L., Wang H., Nakashima N., and Basbaum A.I. Differential effects of intrathecally administered delta and mu opioid receptor agonist on formalin-evoked nociception and on the expression of Fos-like immunoreactivity in the spinal cord of the rat. J Pharmacol Exp Ther 284 (1998) 378-387
11. Hunt S.P., Pini A., and Evan G. Induction of c-fos-like protein in spinal cord neurons following sensory stimulation. Nature 328 (1987) 632-634
12. Jiang Y., Luo L., Gustafson E.L., Yadav D., Laverty M., Murgolo N., Vassileva G., Zeng M., Laz T.M., Behan J., Qiu P., Wang L., Wang S., Bayne M., Greene J., Monsma Jr. F., and Zhang F.L. Identification and characterization of a novel RF-amide peptide ligand for orphan G-protein-coupled receptor SP9155. J Biol Chem 278 (2003) 27652-27657
13. Kalliomaki M.-L., Pertovaara A., Brandt A., Wei H., Pietila P., Kalmari J., Xu M., Kalso E., and Panula P. Prolactin-releasing peptide affects pain, allodynia and autonomic reflexes through medullary mechanisms. Neuropharmacology 46 (2004) 412-424
14. Mollereau C., Mazarguil H., Marcus D., Quelven I., Kotani M., Lannoy V., Dumont Y., Quirion R., Detheux M., Parmentier M., and Zajac J.-M. Pharmacological characterization of human NPFF1 and NPFF2 receptors expressed in CHO cells by using NPY Y1 receptor antagonists. Eur J Pharmacol 451 (2002) 245-256
15. Panula P., Kalso E., Nieminen M.-L., Kontinen V.K., Brandt A., and Pertovaara. Neuropeptide FF and modulation of pain. Brain Res 848 (1999) 191-196
16. Pertovaara A., Ostergard M., Anko M.-L., Lehti-Koivunen S., Brandt A., Hong W., Korpi E.R., and Panula P. RFamide-related peptides signal through the neuropeptide FF receptor and regulate pain-related responses in the rat. Neuroscience 134 (2005) 1023-1032
17. Rudolf K., Eberlein W., Engel W., Wieland H.A., Willim K.D., Entzeroth M., Wienen W., Beck-Sickinger A.G., and Doods H.N. The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP3226. Eur J Pharmacol 271 (1994) R11-R13
18. Snider W.D., and McMahon S.B. Tackling pain at the source: new ideas about nociceptors. Neuron 20 (1998) 629-632
19. Takayasu S., Sakurai T., Iwasaki S., Teranishi H., Yamanaka A., Williams S.C., Iguchi H., Imamura Kawasawa Y., Ikeda Y., Sakakibara I., Ohno K., Ioka R.X., Murakami S., Dohmae N., Xie J., Suda T., Motoike T., Ohuchi T., Yanagisawa M., and Sakai J. A neuropeptide ligand of the G protein-coupled receptor GPR103 regulates feeding, behavioral arousal, and blood pressure in mice. Proc Natl Acad Sci U S A 103 (2006) 7438-7443
20. Wheeler-Aceto H., Porreca F., and Cowan A. The rat formalin test: comparison of noxious agents. Pain 40 (1990) 229-238
21. Yaksh T., and Rudy T.A. Chronic catheterization of the spinal subarachnoid space. Physiol Behav 17 (1976) 1031-1036
22. Yamamoto T., Nozaki-Taguchi N., and Chiba T. Analgesic effect of intrathecally administered orexin-A in the rat formalin test and the rat hot-plate test. Br J Pharmacol 137 (2002) 170-176
23. Yamamoto T., Shimoyama N., and Mizuguchi T. The effects of morphine, MK-801, an NMDA antagonist, and CP-96,345, an NK1 antagonist, on the hyperesthesia evoked by carrageenan injection in the rat paw. Anesthesiology 78 (1993) 124-133
24. Yamamoto T., and Yaksh T.L. Comparison of the antinociceptive effects of pre- and post-treatment with intrathecal morphine and MK801, an NMDA antagonist, on the formalin test in the rat. Anesthesiology 77 (1992) 757-763
25. Yang H.-Y.T., Fratta W., Majane E.A., and Costa E. Isolation, sequencing, synthesis, and pharmacological characterization of two neuropeptides that modulate the action of morphine. Proc Natl Acad Sci U S A 82 (1985) 7757-7761